OBJECTIVE: To investigate the changes in expression profile of circulating microRNAs (miRNAs) and the regulatory effect of atrial fibrilation (AF)-related miRNAs on ion channels. METHODS: 112 patients with AF were assigned into observation group, and another 112 non-AF people were assigned into control group. Total plasma RNAs were extracted from patients' blood samples. Differentially expressed miRNA-1s were transfected into primary-cultured neonatal rat cardiac myocytes. RESULTS: Compared with control group, significant differences were observed in 15 kinds of miRNAs in observation group. Down-regulation of the expression of miRNAs included hsa-miR-328, hsa-miR-145, hsa-miR-222, hsa-miR-1, hsa-miR-162, hsa-miR-432, and hsa-miR-493b; Up-regulation of the expression included hsa-miR634, hsa-miR-664, hsa-miR-9, hsa-miR-152, hsa-miR-19, hsa-miR-454, hsa-miR-146, and hsa-miR-374a. The expression level of CACNB2 protein in miRNA-1 group was significantly lower than that in blank control group, negative control group, MTmiRNA-1 group, AMO-1 group and miRNA-1+AMO-1 cotransfection group (P < 0.05), while in AMO-1 group, the expression level of CACNB2 protein was significantly higher than that in other groups (P < 0.05). These results indicated that transfected miRNA-1 could significantly inhibit the expression of CACNB2 protein. CONCLUSIONS: Circulating miRNAs can be used in studies concerning on the regulation mechanism of the occurrence and development of AF. MiRNA-1 can decrease the intracellular Ca(2+) concentration and prevent the AF.
OBJECTIVE: To investigate the changes in expression profile of circulating microRNAs (miRNAs) and the regulatory effect of atrial fibrilation (AF)-related miRNAs on ion channels. METHODS: 112 patients with AF were assigned into observation group, and another 112 non-AFpeople were assigned into control group. Total plasma RNAs were extracted from patients' blood samples. Differentially expressed miRNA-1s were transfected into primary-cultured neonatal rat cardiac myocytes. RESULTS: Compared with control group, significant differences were observed in 15 kinds of miRNAs in observation group. Down-regulation of the expression of miRNAs included hsa-miR-328, hsa-miR-145, hsa-miR-222, hsa-miR-1, hsa-miR-162, hsa-miR-432, and hsa-miR-493b; Up-regulation of the expression included hsa-miR634, hsa-miR-664, hsa-miR-9, hsa-miR-152, hsa-miR-19, hsa-miR-454, hsa-miR-146, and hsa-miR-374a. The expression level of CACNB2 protein in miRNA-1 group was significantly lower than that in blank control group, negative control group, MTmiRNA-1 group, AMO-1 group and miRNA-1+AMO-1 cotransfection group (P < 0.05), while in AMO-1 group, the expression level of CACNB2 protein was significantly higher than that in other groups (P < 0.05). These results indicated that transfected miRNA-1 could significantly inhibit the expression of CACNB2 protein. CONCLUSIONS: Circulating miRNAs can be used in studies concerning on the regulation mechanism of the occurrence and development of AF. MiRNA-1 can decrease the intracellular Ca(2+) concentration and prevent the AF.
Authors: Dmitry Terentyev; Andriy E Belevych; Radmila Terentyeva; Mickey M Martin; Geraldine E Malana; Donald E Kuhn; Maha Abdellatif; David S Feldman; Terry S Elton; Sandor Györke Journal: Circ Res Date: 2009-01-08 Impact factor: 17.367
Authors: Zhenji Gan; John Rumsey; Bethany C Hazen; Ling Lai; Teresa C Leone; Rick B Vega; Hui Xie; Kevin E Conley; Johan Auwerx; Steven R Smith; Eric N Olson; Anastasia Kralli; Daniel P Kelly Journal: J Clin Invest Date: 2013-05-08 Impact factor: 14.808
Authors: Nicoline W E van den Berg; Makiri Kawasaki; Wouter R Berger; Jolien Neefs; Eva Meulendijks; Anke J Tijsen; Joris R de Groot Journal: Cardiovasc Drugs Ther Date: 2017-06 Impact factor: 3.727
Authors: Claudio de Lucia; Klara Komici; Giulia Borghetti; Grazia Daniela Femminella; Leonardo Bencivenga; Alessandro Cannavo; Graziamaria Corbi; Nicola Ferrara; Steven R Houser; Walter J Koch; Giuseppe Rengo Journal: Front Med (Lausanne) Date: 2017-06-12
Authors: Ananília Medeiros Gomes da Silva; Jéssica Nayara Góes de Araújo; Renata Caroline Costa de Freitas; Vivian Nogueira Silbiger Journal: Biomed Res Int Date: 2017-03-02 Impact factor: 3.411
Authors: Shan-Shan Zhou; Jing-Peng Jin; Ji-Qun Wang; Zhi-Guo Zhang; Jonathan H Freedman; Yang Zheng; Lu Cai Journal: Acta Pharmacol Sin Date: 2018-06-07 Impact factor: 6.150